EVERSANA joins with Veeva in push to 'pharmatise AI'

Commercial services player EVERSANA has joined the growing number of companies partnering with Veeva Systems – a specialist in cloud software for the life sciences industry – on the development of artificial intelligence solutions for the sector.

EVERSANA is joining more than 20 organisations in Veeva's AI Partner Programme, first launched in April 2024, which provides access to technology and support needed to integrate generative AI (GenAI) that can work with Veeva's Vault platform.

Vault is a cloud-based platform and suite of applications for customer relationship management (CRM) – aimed at unifying sales, marketing, and medical operations – with software to help streamline a host of other functions, including clinical trials, manufacturing, and quality control.

It is a leading player in a CRM market, estimated at around $4.4 billion last year and tipped to grow to more than $6.6 billion by 2033, driven by the increasing focus of life sciences companies on building and managing relationships with healthcare professionals (HCPs) and other stakeholders, according to forecaster CMI Consulting.

GenAI has become a hot topic in the category, and at the time the AI partner programme launched, Veeva's president and chief customer officer, Tom Schwenger, said the company's customers were "exploring GenAI solutions across many use cases as the technology evolves."

EVERSANA – pharmaphorum's parent company – said it has met the standard to join Veeva's partner programme and will now be able to use Veeva's application sandbox to develop, test, and support partner applications integrated with Vault applications and "help solve client challenges."

That includes the usage of Veeva PromoMats, which streamlines the creation, review, and distribution of compliant content at scale, according to the company.

"As a Veeva AI Partner, the sky is the limit in our team's ability to develop and deploy transformational solutions to help our clients," said Jim Lang, EVERSANA's chief executive.

"Together we'll push each other to ensure our commitment to innovation and ability to 'pharmatise AI' remains unwavering," he added.

The new relationship comes on the heels of a string of other partnerships that EVERSANA has forged to expand its capabilities.

In January, the company joined forces with Lyfegen on drug pricing and market access resources, and towards the end of last year teamed up with Oracle Argus Cloud on a pharmacovigilance project that followed alliances with Amazon Web Services and Adobe Firefly, focused respectively on applying GenAI for medical and regulatory content approvals and personalised content for patients, providers, and payers.

Photo by Evgeniy Alyoshin on Unsplash